611 related articles for article (PubMed ID: 20709811)
21. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
23. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.
Slupianek A; Yerrum S; Safadi FF; Monroy MA
J Cell Physiol; 2010 Aug; 224(2):369-75. PubMed ID: 20432434
[TBL] [Abstract][Full Text] [Related]
24. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
25. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
[TBL] [Abstract][Full Text] [Related]
27. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
28. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
29. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
van der Poel HG
Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.
Marcias G; Erdmann E; Lapouge G; Siebert C; Barthélémy P; Duclos B; Bergerat JP; Céraline J; Kurtz JE
Hum Mutat; 2010 Jan; 31(1):74-80. PubMed ID: 19830810
[TBL] [Abstract][Full Text] [Related]
33. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
34. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
35. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.
Jung C; Kim RS; Zhang HJ; Lee SJ; Jeng MH
Cancer Res; 2004 Dec; 64(24):9185-92. PubMed ID: 15604291
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation increases p300 expression in prostate cancer cells.
Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
[TBL] [Abstract][Full Text] [Related]
39. CDC25A functions as a novel Ar corepressor in prostate cancer cells.
Chiu YT; Han HY; Leung SC; Yuen HF; Chau CW; Guo Z; Qiu Y; Chan KW; Wang X; Wong YC; Ling MT
J Mol Biol; 2009 Jan; 385(2):446-56. PubMed ID: 19013180
[TBL] [Abstract][Full Text] [Related]
40. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]